New Zealand funds Zyban after GSK deal
This article was originally published in Scrip
Executive Summary
The New Zealand pharmaceutical management agency Pharmac is to fund the smoking cessation product Zyban (bupropion) from July 1st, after reaching a deal with its manufacturer, GlaxoSmithKline.